论文部分内容阅读
目的探讨LOH12CR1在结直肠癌中的表达以及与临床病理的关系。方法在北京大学深圳医院确诊并行根治术的109例结直肠癌患者纳入本次研究,取各受试者结直肠癌组织和癌旁5 cm正常组织作术后病理蜡块标本,采用免疫组化法测定LOH12CR1,并分析LOH12CR1表达与结直肠癌患者临床病理特征的关系。结果结直肠癌患者癌组织LOH12CR1表达的阳性率为51.38%,癌旁5 cm正常组织表达的阳性率为77.98%,癌组织较正常组织表达水平显著降低(P<0.01);结直肠癌组织LOH12CR1,随着患者肿瘤TNM和Dukes分期、分化程度、有无淋巴结转移的差异而呈不同表达(P<0.01)。结论 LOH12CR1可能参与结直肠癌发生、发展,并且与结直肠癌的分化和转移有关,可望成为用于结直肠癌诊断、生物靶向治疗、监测复发的新的肿瘤标记物。
Objective To investigate the expression of LOH12CR1 in colorectal cancer and its relationship with clinical pathology. Methods One hundred and ninety-nine patients with colorectal cancer diagnosed concurrent radical surgery at Peking University Shenzhen Hospital were enrolled in this study. The specimens of colorectal cancer tissues and para-cancerous tissues of 5 cm each were taken as pathological wax specimens. Immunohistochemistry Method to determine LOH12CR1, and analyze the relationship between LOH12CR1 expression and clinicopathological features of patients with colorectal cancer. Results The positive rate of LOH12CR1 expression in colorectal cancer tissues was 51.38%, the positive rate of 5 cm normal colorectal cancer tissues was 77.98%, and the expression of LOH12CR1 in colorectal cancer tissues was significantly lower than that in normal tissues (P <0.01) , With different expression of tumor TNM and Dukes stage, differentiation degree, with or without lymph node metastasis (P <0.01). Conclusions LOH12CR1 may be involved in the development and progression of colorectal cancer and is related to the differentiation and metastasis of colorectal cancer. It may be a new tumor marker for the diagnosis of colorectal cancer, bio-targeted therapy and recurrence monitoring.